195 results
6-K
TAK
Takeda Pharmaceutical Co
27 May 20
Current report (foreign)
6:13am
to establish performance targets and to assess the relative weighting for each KPI. Underlying KPIs reflect the understanding that divestitures … plans are designed in a way that allows participants to be rewarded for delivering strong results for shareholders if Takeda exceeds the plan targets
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
21 Jun 21
Current report (foreign)
6:05am
performance targets and to assess the relative weighting for each KPI. Underlying KPIs reflect the understanding that divestitures and significant events … are designed in a way that allows participants to be rewarded for delivering strong results for shareholders if Takeda exceeds the plan targets. Conversely
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
28 May 21
Current report (foreign)
6:07am
targets and to assess the relative weighting for each KPI. Underlying KPIs reflect the understanding that divestitures and significant events … in a way that allows participants to be rewarded for delivering strong results for shareholders if Takeda exceeds the plan targets. Conversely, if Takeda
6-K
TAK
Takeda Pharmaceutical Co
6 Aug 21
Current report (foreign)
6:10am
with Takeda’s peer group.
The Committee and the Board reference the annual operating plan to establish performance targets and to assess the relative … to be rewarded for delivering strong results for shareholders if Takeda exceeds the plan targets. Conversely, if Takeda does not achieve targets
6-K
TAK
Takeda Pharmaceutical Co
31 May 22
Current report (foreign)
6:18am
performance targets and to assess the relative weighting for each KPI. Underlying KPIs reflect the understanding that divestitures and significant … are designed in a way that allows participants to be rewarded for delivering strong results for shareholders if Takeda exceeds the plan targets
6-K
woh72pzjvl7hp
31 Jul 19
Current report (foreign)
6:42am
6-K
juh6nf7
30 May 23
Current report (foreign)
6:20am
6-K
bjbcpzh
29 Jun 20
Current report (foreign)
7:54am
6-K
qm1bhc2by59dr
29 Jun 20
Current report (foreign)
7:49am
6-K
eyq8loeakgr8fsp57
14 Nov 19
Current report (foreign)
6:14am
6-K
EX-99.1
5xvzmlzvmoj9
9 May 24
Current report (foreign)
6:08am
6-K
EX-99.1
xxkyrfj2ws
13 Dec 22
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
7:00am
6-K
ebj9zs3
11 May 21
Current report (foreign)
6:15am
6-K
o9cuj2uor
9 Feb 24
Current report (foreign)
6:03am
6-K
nllz6o
13 Dec 22
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
7:00am
6-K
g3m4t2rm1rc8
11 May 23
Current report (foreign)
6:10am
6-K
wxf1tb 2c8hmb8d4
11 May 22
Current report (foreign)
6:11am
6-K
9dodypjt71g u0py0x
14 Jan 20
Current report (foreign)
6:56am
6-K
knwxepzg7niqvegjx32
25 Jun 20
Current report (foreign)
6:07am
6-K
2wcyy 4tpa7x
16 Dec 19
Current report (foreign)
6:10am